Nestlé Health Science partners with Enterome to treat food allergies and bowel inflammation

In a newly inked deal with Nestlé Health Science, the French firm partly owned by the Lundbeck Foundation will zoom in on inflammatory bowel disease (IBD) and food allergies, beginning with peanuts.

Photo: Frank Molter/AP/Ritzau Scanpix

French Biotech firm Enterome, partly owned by the Lundbeck Foundation, has entered a strategic research and development partnership regarding food allergies and inflammatory bowel disease (IBD) with Nestlé Health Science, according to a company press release.

Enterome describes two specific goals of the collaboration, the first of which concerns the successful development and commercialization of Enterome’s pipeline candidate slated for clinical testing next year, EB1010, a potential treatment for IBD and food allergies.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs